Beta3 Integrin and Src Facilitate Transforming Growth Factor-beta Mediated Induction of Epithelial-mesenchymal Transition in Mammary Epithelial Cells

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2006 Jul 25

PMID 16859511

Citations 138

Authors

Amy J Galliher

William P Schiemann

Affiliations

Soon will be listed here.

Abstract

Introduction: Transforming growth factor (TGF)-beta suppresses breast cancer formation by preventing cell cycle progression in mammary epithelial cells (MECs). During the course of mammary tumorigenesis, genetic and epigenetic changes negate the cytostatic actions of TGF-beta, thus enabling TGF-beta to promote the acquisition and development of metastatic phenotypes. The molecular mechanisms underlying this conversion of TGF-beta function remain poorly understood but may involve signaling inputs from integrins.

Methods: beta3 Integrin expression or function in MECs was manipulated by retroviral transduction of active or inactive beta3 integrins, or by transient transfection of small interfering RNA (siRNA) against beta3 integrin. Altered proliferation, invasion, and epithelial-mesenchymal transition (EMT) stimulated by TGF-beta in control and beta3 integrin manipulated MECs was determined. Src involvement in beta3 integrin mediated alterations in TGF-beta signaling was assessed by performing Src protein kinase assays, and by interdicting Src function pharmacologically and genetically.

Results: TGF-beta stimulation induced alphavbeta3 integrin expression in a manner that coincided with EMT in MECs. Introduction of siRNA against beta3 integrin blocked its induction by TGF-beta and prevented TGF-beta stimulation of EMT in MECs. beta3 integrin interacted physically with the TGF-beta receptor (TbetaR) type II, thereby enhancing TGF-beta stimulation of mitogen-activated protein kinases (MAPKs), and of Smad2/3-mediated gene transcription in MECs. Formation of beta3 integrin:TbetaR-II complexes blocked TGF-beta mediated growth arrest and increased TGF-beta mediated invasion and EMT. Dual beta3 integrin:TbetaR-II activation induced tyrosine phosphorylation of TbetaR-II, a phosphotransferase reaction mediated by Src in vitro. Inhibiting Src activity in MECs prevented the ability of beta3 integrin to induce TbetaR-II tyrosine phosphorylation, MAPK activation, and EMT stimulated by TGF-beta. Lastly, wild-type and D119A beta3 integrin expression enhanced and abolished, respectively, TGF-beta stimulation of invasion in human breast cancer cells.

Conclusion: We show that beta3 integrin alters TGF-beta signaling in MECs via Src-mediated TbetaR-II tyrosine phosphorylation, which significantly enhanced the ability of TGF-beta to induce EMT and invasion. Our findings suggest that beta3 integrin interdiction strategies may represent an innovative approach to re-establishing TGF-beta mediated tumor suppression in progressing human breast cancers.

Citing Articles

Role of the integrin‑β1/TGF‑β1 signaling pathway in the pathogenesis of pelvic organ prolapse: A study on vaginal wall tissue alterations and molecular dysfunction.

Kong M, Wang Z, Hao Y, Shi Y, Yang X, Djurist N Mol Med Rep. 2025; 31(4).

PMID: 39981910 PMC: 11876943. DOI: 10.3892/mmr.2025.13469.

Prostate Cancer Bone Metastasis: Molecular Mechanisms of Tumor and Bone Microenvironment.

Jiang H Cancer Manag Res. 2025; 17:219-237.

PMID: 39912095 PMC: 11796448. DOI: 10.2147/CMAR.S495169.

Role of integrins in the development of fibrosis in the trabecular meshwork.

Faralli J, Filla M, Peters D Front Ophthalmol (Lausanne). 2024; 3:1274797.

PMID: 38983065 PMC: 11182094. DOI: 10.3389/fopht.2023.1274797.

Comprehensive molecular interaction map of TGFβ induced epithelial to mesenchymal transition in breast cancer.

Gottumukkala S, Ganesan T, Palanisamy A NPJ Syst Biol Appl. 2024; 10(1):53.

PMID: 38760412 PMC: 11101644. DOI: 10.1038/s41540-024-00378-w.

Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective.

Danielpour D Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675493 PMC: 11054419. DOI: 10.3390/ph17040533.

References

DeCoteau J, Knaus P, Yankelev H, Reis M, Lowsky R, Lodish H . Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1997; 94(11):5877-81. PMC: 20874. DOI: 10.1073/pnas.94.11.5877. View

Lawler S, Feng X, Chen R, Maruoka E, Turck C, Derynck R . The type II transforming growth factor-beta receptor autophosphorylates not only on serine and threonine but also on tyrosine residues. J Biol Chem. 1997; 272(23):14850-9. DOI: 10.1074/jbc.272.23.14850. View

Bottinger E, Jakubczak J, Haines D, Bagnall K, Wakefield L . Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res. 1998; 57(24):5564-70. View

CARY L, Guan J . Focal adhesion kinase in integrin-mediated signaling. Front Biosci. 1999; 4:D102-13. DOI: 10.2741/cary. View

Maeda M, Shintani Y, Wheelock M, Johnson K . Src activation is not necessary for transforming growth factor (TGF)-beta-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II. J Biol Chem. 2005; 281(1):59-68. DOI: 10.1074/jbc.M503304200. View

Bose R, Wrana J . Regulation of Par6 by extracellular signals. Curr Opin Cell Biol. 2006; 18(2):206-12. DOI: 10.1016/j.ceb.2006.02.005. View

Arias-Salgado E, Lizano S, Sarkar S, Brugge J, Ginsberg M, Shattil S . Src kinase activation by direct interaction with the integrin beta cytoplasmic domain. Proc Natl Acad Sci U S A. 2003; 100(23):13298-302. PMC: 263791. DOI: 10.1073/pnas.2336149100. View

Albini A, Iwamoto Y, Kleinman H, Martin G, Aaronson S, Kozlowski J . A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987; 47(12):3239-45. View

Mizejewski G . Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med. 1999; 222(2):124-38. DOI: 10.1177/153537029922200203. View

10.

Piek E, Moustakas A, Kurisaki A, Heldin C, Ten Dijke P . TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci. 1999; 112 ( Pt 24):4557-68. DOI: 10.1242/jcs.112.24.4557. View

11.

Blobe G, Schiemann W, Lodish H . Role of transforming growth factor beta in human disease. N Engl J Med. 2000; 342(18):1350-8. DOI: 10.1056/NEJM200005043421807. View

12.

Sieg D, Hauck C, Ilic D, Klingbeil C, Schaefer E, Damsky C . FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol. 2000; 2(5):249-56. DOI: 10.1038/35010517. View

13.

Lehmann K, Janda E, Pierreux C, Rytomaa M, Schulze A, McMahon M . Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev. 2000; 14(20):2610-22. PMC: 316988. DOI: 10.1101/gad.181700. View

14.

Massague J, Blain S, Lo R . TGFbeta signaling in growth control, cancer, and heritable disorders. Cell. 2000; 103(2):295-309. DOI: 10.1016/s0092-8674(00)00121-5. View

15.

Bakin A, Tomlinson A, Bhowmick N, Moses H, Arteaga C . Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem. 2000; 275(47):36803-10. DOI: 10.1074/jbc.M005912200. View

16.

Bhowmick N, Ghiassi M, Bakin A, Aakre M, Lundquist C, Engel M . Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell. 2001; 12(1):27-36. PMC: 30565. DOI: 10.1091/mbc.12.1.27. View

17.

Felding-Habermann B, OToole T, Smith J, Fransvea E, Ruggeri Z, Ginsberg M . Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A. 2001; 98(4):1853-8. PMC: 29346. DOI: 10.1073/pnas.98.4.1853. View

18.

Santner S, Dawson P, Tait L, SOULE H, Eliason J, Mohamed A . Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat. 2001; 65(2):101-10. DOI: 10.1023/a:1006461422273. View

19.

Hocevar B, Smine A, Xu X, Howe P . The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J. 2001; 20(11):2789-801. PMC: 125498. DOI: 10.1093/emboj/20.11.2789. View

20.

Zavadil J, Bitzer M, Liang D, Yang Y, Massimi A, Kneitz S . Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc Natl Acad Sci U S A. 2001; 98(12):6686-91. PMC: 34413. DOI: 10.1073/pnas.111614398. View